Hope for 'Glass Men': Breakthroughs in Hemophilia Therapies Signal a New Era of Treatment

　　【Pharmaceutical Network Industry Dynamics】Hemophilia is a group of hereditary bleeding disorders caused by coagulation dysfunction, and patients are referred to as "glass people." As one of the major types of rare diseases, there are currently about 136,000 hemophilia patients in China. At present, the standard treatment for hemophilia involves preventive intravenous injections of clotting factors 2-3 times per week. However, this method comes with issues such as high infusion frequency, poor treatment adherence, inability to ensure consistently adequate preventive treatment, and a high disability rate. Therefore, the clinical demand for drug innovation is increasing, and the significant financial burden on patients also urgently needs to be addressed.
 

Recently, there has been good news in the field of hemophilia treatment. At the 6th CIIE, Sanofi presented Fitusiran, an innovative drug under research and the world's first siRNA therapy applied in the field of hemophilia, which will bring a new preventive treatment option for patients with Hemophilia A/B.
 

Small interfering RNA (siRNA) therapy is a novel treatment approach that works by interfering with the production of specific proteins. Fitusiran, developed by Sanofi, is the first siRNA therapy for hemophilia, targeting antithrombin to enhance blood clotting function. It is the first new prophylactic hemostatic method effective for both patients with and without inhibitors in those suffering from Hemophilia A and B. With the advantage of convenient administration, it requires only six or more subcutaneous injections per year, effectively controlling bleeding and significantly improving patients' quality of life.
 

Roche developed the bispecific antibody Hemlibra (emicizumab) for bleeding control in the hemophilia field early on. At this year's CIIE, Roche China announced the "Orange Sailing Treasure Plan," which focuses on the needs of hemophilia patients and provides support in multiple dimensions such as physical, financial, and emotional aspects. Among these efforts, Beijing Chenxi Health Technology Co., Ltd., a subsidiary of Sinopharm Holding, will enhance the accessibility and affordability of the innovative treatment drug emicizumab through commercial insurance claims, offering help to hemophilia patients, especially children in critical treatment stages and their families.

 

In addition, Pfizer Rare Disease held relevant themed activities during the exhibition, aiming to focus on innovative exploration of hemophilia treatment models and the upgrading of therapeutic drugs. Together with various parties, it is promoting the practice of "standardized diagnosis and treatment, localized management." Among these efforts, Pfizer has put forward for the first time in the industry the concept of hemophilia diagnosis and treatment: "Dual-dimension compliance, freedom through mastery," continuously advancing clinical diagnosis and treatment development and comprehensive patient care until the goal of "breaking free from the constraints of the disease" is achieved. This initiative aims to "restart a life of freedom and illuminate a better life" for hemophilia patients in China, while providing experience and a model for the construction of a rare disease diagnosis and treatment system in China.
 

It is reported that Pfizer is also actively deploying non-factor therapy and gene therapy for hemophilia, aiming to meet the clinical needs of some hemophilia patients whose symptoms cannot be relieved after receiving factor replacement therapy. Pfizer's non-factor therapy has a unique mechanism of action, helping patients re-establish the balance between bleeding and coagulation. It adopts a fixed dose and is administered subcutaneously once a week, treating either Hemophilia A or B. Currently, China has joined the global research for synchronized development, hoping to benefit domestic patients as soon as possible.
 

With the continuous efforts of leading multinational pharmaceutical companies in exploring more innovative drug research and development, innovative therapies, and comprehensive support for patients, it is believed that hemophilia patients will be better able to break free from the constraints of their condition and return to normal social life sooner.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.